Economic Impact

Anticipated economic benefits of T2Bacteria

Bacterial bloodstream infections are very common, and the pathogens covered by the T2Bacteria™ Panel, clinical trials in the US and performance evaluations in the EU, are among the most deadly and costly to treat. A wide variety of studies have documented that getting the right treatment to patients with bacterial bloodstream infections within the first 24 hours of presentation can yield cost savings in the range of $22,000 to $38,000 per patient.1-7 With its unmatched combination of speed and sensitivity, the T2Bacteria Panel is projected to help hospitals achieve savings similar to those already demonstrated by the T2Candida® Panel. 

In addition, negative T2Bacteria results will provide significant economic and clinical value once commercially available. A negative result may enable physicians to discontinue the use of expensive empiric therapies or substitute with effective and less expensive therapies, potentially reducing the cost of care by up to $500 per patient.

Expected length of stay reductions with appropriate Rx in 1st 24 hours based on published data

 

 

E. faecium 1

S. aureus 2

K. pneumoniae 3

A. baumannii 4

P. aeruginosa 5

E. coli 6

ICU (days) 3 5 4 7 7 4
Hospital (days) 7 3 4 1 6 4

 

 

 

 

Cost per ICU Day7 $4,150
Cost per Hospital Day7 $1,560

 

 

 

E. faecium 1

S. aureus 2

K. pneumoniae 3

A. baumannii 4

P. aeruginosa 5

E. coli 6

Total Length of Stay savings

per positive patient

$23,400 $25,400 $22,800 $29,100 $38,400 $22,800

 

 


 

Patients presenting in hospitals, including emergency departments (ED)

  • Hospital inpatients are reimbursed under DRG codes and all cost savings associated with T2MR testing accrue to the hospital

  • 50-60% of sepsis episodes are diagnosed in the ED8

  • Most common pathogenic isolates in ED

    • Staphylococcus aureus (34.1%) and Escherichia coli (22.8%) accounted for 56.9%9

  • Existing CDPT codes provide over $290 of reimbursement per T2Bacteria test10

  • Hospital CLABSI rates can be improved by an accurate detection for inpatients or in the ED by properly identifying patients with infections that might otherwise be classified as Hospital Acquired Infections

……………………………………….

1. Stosor V et al. Enterococcus faecium bacteremia: does vancomycin resistance make a difference? Arch Intern Med. 1998 Mar 9;158(5):522-7.
2. Abramson MA et al. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs? Infect Control Hosp Epidemiol. 1999 Jun;20(6):408-11.
3. Kim BN et al. Clinical implications of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteraemia. J Hosp Infect. 2002 Oct;52(2):99-106.
4. Sunenshine RH et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis. 2007 Jan;13(1):97-103.
5. Micek ST et al. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother. 2005 Apr;49(4):1306-11.
6. Tumbarello M et al. Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-beta-lactamase production and inadequate initial antibiotic therapy. Antimicrob Agents Chemother. 2010 Oct;54(10):4085-91.
7. Golan, Yoav, et al. Annals of internal medicine 143.12 (2005): 857-869.
8. Garnacho-Montero, J., Gutiérrez-Pizarraya, A., Escoresca-Ortega, A., Fernández-Delgado, E., & López-Sánchez, J. M. (2015). Adequate antibiotic therapy prior to ICU admission in patients with severe sepsis and septic shock reduces hospital mortality. Critical care, 19(1), 302.
9. Tsalik, E. L., Jones, D., Nicholson, B., Waring, L., Liesenfeld, O., Park, L. P., … & Cairns, C. B. (2010). Multiplex PCR to diagnose bloodstream infections in patients admitted from the emergency department with sepsis. Journal of clinical microbiology, 48(1), 26-33.
10. This information is provided for illustrative purposes and cannot cover all situations or all third-party payers’ rules or policies, nor can use of the information guarantee coverage or payment. CPT is a registered trademark of the American Medical Association (AMA). All rights reserved.